Introduction of human papillomavirus DNA screening in the world: 15 years of experience

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Castle, Philip E ^a   de Sanjosé, Silvia ^b,c   Qiao, You Lin ^d   Belinson, Jerome L ^e   Lazcano Ponce, Eduardo ^f   Kinney, Walter ^g  

^a American Society for Clinical Pathology   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^f INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^g KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Cytology; HPV; Pap testing; Screening; Triage

Indexed keywords

VIRUS DNA;

AFRICA; ASIA; CANCER INCIDENCE; CANCER RISK; DIAGNOSTIC TEST; DNA SCREENING; EMERGENCY HEALTH SERVICE; EUROPE; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INDIA; ITALY; MEXICO; NETHERLANDS; PAPANICOLAOU TEST; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SAMPLE SIZE; SPAIN; SWEDEN; TURKEY (REPUBLIC); UNITED KINGDOM; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84877075018     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.071     Document Type: Review

References (38)

1. Cervix cancer screening.IARC Press. IARC Handbooks of Cancer Prevention. Volume 10. Lyon, 2005.
2. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006 Sep 1;119(5):1095-101.
3. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007 Oct 18;357(16):1579-88.
4. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007 Oct 18;357(16):1589-97.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010 Mar;11(3):249-57.
6. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010 Apr 27;340:c1804, http://dx.doi.org/10.1136/bmj.c1804.:c1804.
7. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012 Jan;13(1):78-88.
8. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Schiffman M, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011 Mar;117(3):650-6.
9. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009 Apr 2;360(14):1385-94.
10. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001 Feb 21;93(4):293-9.
11. Wright Jr TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002 Apr 24;287(16):2120-9.
12. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011 Jul;12(7):663-72.
13. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002 Nov;52(6):342-62.
14. ACOG Practice Bulletin No. 109: Cervical Cytology Screening. Obstet Gynecol 2009;114(6):1409-20.
15. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62(3):147-72, http://dx.doi.org/10.3322/caac.21139. Epub 2012 Mar 14.
16. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Low Genit Tract Dis 2012 Mar 13.
17. Moyer VA. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012 Mar 14.
18. Chelmow D, Waxman A, Cain JM, Lawrence III HC. The evolution of cervical screening and the specialty of obstetrics and gynecology. Obstet Gynecol 2012 Apr;119(4):695-9.
19. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with HPV and the Pap test vs. the Pap test alone: what screening intervals are physicians recommending? Arch Intern Med 2010 Jun 14;170(11):977-85.
20. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 2011 Jul;118(1):4-13.
21. Castle PE, Fetterman B, Thomas CJ, Shaber R, Poitras N, Lorey T, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010 Jul;116(1):76-84.
22. Yabroff KR, Saraiya M, Meissner HI, Haggstrom DA, Wideroff L, Yuan G, et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med 2009 Nov 3;151(9):602-11.
23. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011 Nov 26;378(9806): 1868-73.
24. Anttila A, Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009 Oct;45(15):2685-708.
25. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009 Jul;10(7):672-82.
26. Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol 2009 Sep;10(9):841-2.
27. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011 Apr;47(6):864-71.
28. Barzon L, Giorgi C, Buonaguro FM, Palu G. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer 2008 Dec 16;3:14.:14.
29. Puig-Tintore LM, Torne A, Alonso I. Current techniques in screening for cervical cancer in Spain: updated recommendations. Gynecol Oncol 2008 Sep;110(3 Suppl 2):S8-10.
30. Ibanez R, Moreno-Crespi J, Sarda M, Autonell J, Fibla M, Gutiérrez C, et al. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cells of undetermined significance (ASC-US) in Catalonia. Spain BMC Infect Dis 2012 Jan 26;12(1): 25.
31. Belinson J, Qiao Y, Pretorius R, et al. Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer 1999 Sep;9(5):411-7.
32. Belinson JL, Qiao YL, Pretorius RG, Zhang W, Keaton K, Elson P, et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003 Nov;13(6): 819-26.
33. Women's health in rural China. Lancet 2009 Aug 1;374(9687):358.
34. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007 Aug 4;370(9585):398-406.
35. Denny L, Kuhn L, Hu CC, Tsai WY, Wright Jr TC. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010 Oct;102(20):1557-67.
36. Sadique MZ, Legood R. Women's preferences regarding options for management of atypical, borderline or low-grade cervical cytological abnormalities: a review of the evidence. Cytopathology 2011 Jun;9:10-2303.
37. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer 2008 Jul;18(4):743-8.
38. Gage JC, Castle PE. Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst 2010 Oct;102(20):1524-7.